Company Overview and News

 
Britain's Capita raises 681 mln pounds to pay down debt

20h reuters
May 25 (Reuters) - Britain’s Capita Plc said on Friday it raised 681.4 million pounds ($911 million) through a rights issue aimed at paying down debt, plugging a pension deficit and boosting investment.

 
Chinese internet firm Sina ‘planning secondary share listing in Hong Kong’

20h scmp
The listing is likely to take place in the fourth quarter and comes after the Hong Kong bourse changes its listing rules

 
BGHL (EUR): NAV(s)

20h globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 
BGHL (GBP): NAV(s)

20h globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 
Lonmin: Red Flags Persist

2018-05-23 seekingalpha
Audit findings on Lonmin Plc (OTC:LNMIF)(OTCPK:LNMIY) reveal that the company is being flagged due to evidence of "material uncertainty" as a going concern and non-cash impairment of the carrying value of LNMIY's assets. Note that any further impairment could result in breaching its tangible net worth financial covenant. However, the Board reassured its stakeholders that it is currently addressing these issues as part of its operational restructuring plan that included the shutting down of old shafts.

 
BGHL (EUR): NAV(s)

2018-05-23 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 
BGHL (GBP): NAV(s)

2018-05-23 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 
Michael Spencer bids 'good farewell' as Nex edges closer to CME takeover 

2018-05-22 telegraph.co.uk
Michael Spencer has used his company's last set of results before it is swallowed up by American giant CME to unveil further cost cuts, welcome market volatility, and "bid a good farewell".

 
Serabi Gold plc : Holding in Company - TR1 Notification

2018-05-22 globenewswire
For immediate release 22 May 2018 Serabi Gold plc ("Serabi" or the "Company") Holding(s) in Company

 
Is Antofagasta Still The Best Way To Gain Exposure To Copper?

2018-05-22 seekingalpha
Antofagasta saw its operating income more than double in 2017 on the back of higher copper prices.

 
Doc re. GE Files Form 8-K

2018-05-22 globenewswire
On May 21, 2018, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports.

 
ProPhotonix Announces that its Laser Facility has Achieved ISO9001: 2015

2018-05-22 accesswire
SALEM, NH / ACCESSWIRE / May 22, 2018 / ProPhotonix Limited (OTC PINK: STKR; AIM: PPIX), a high technology designer and manufacturer of LED illumination systems and laser diode modules, with operations in Ireland and the United Kingdom, is pleased to announce that its UK subsidiary has successfully transitioned from ISO9001:2008 to ISO9001:2015. ProPhotonix (UK) Limited, the Company's laser manufacturing facility, has been continuously certified to the ISO9001 standard since 2003.

 
BGHL (EUR): NAV(s)

2018-05-22 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 
BGHL (GBP): NAV(s)

2018-05-22 globenewswire
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 
Flash - Britain turning 'blind eye' to corrupt Russian cash: MPs - France 24

2018-05-21 france24
British MPs urged the government Monday to clamp down on corrupt Russian money flowing through London, warning that turning a "blind eye" risked undermining its tough approach to Moscow.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 54211N101